Research Article

Development of a UV-Vis Spectroscopic Method for Etodolac Determination and Evaluation of Pharmaceutical Additive Effects

Volume: 8 Number: 3 December 23, 2025
EN TR

Development of a UV-Vis Spectroscopic Method for Etodolac Determination and Evaluation of Pharmaceutical Additive Effects

Abstract

Etodolac is an active substance from the nonsteroidal anti-inflammatory drug (NSAID) class and is widely used in the treatment of pain and inflammation. In this study, a simple, rapid, and sensitive UV-Vis spectrophotometric method was developed and validated for the quantitative determination of etodolac from commercial tablet formulations. Etodolac showed maximum absorbance at 278 nm. Methanol was optimized as the most suitable solvent in the study, and the method was validated according to these conditions. The method demonstrated a linear working range of 0.88- 40 µg mL-1. The limit of detection (LOD) was found to be 0.29 µg mL-1. Additionally, the effects of some pharmaceutical excipients on the UV absorbance of etodolac were investigated. Pharmaceutical excipients can cause changes in the UV absorbance of the active ingredient, which can lead to incorrect dosage determinations and analytical errors. In this context, the effect of mannose, lactose monohydrate, and potassium sorbate on the maximum absorbance of etodolac at 278 nm was evaluated, and possible interferences were examined. In addition, stability studies were carried out for four weeks to test the long-term reliability of the analysis method. Moreover, the recovery of etodolac from the Etotio tablet formulation was measured, and the method's accuracy was evaluated. The data showed that the applied analysis method offers high precision, reproducibility, and reliability. This study presents an optimized, sensitive, and selective method for accurately quantifying etodolac in pharmaceutical preparations.

Keywords

Ethical Statement

The study is proper with ethical standards.

Thanks

The authors thank Dr. İbrahim Murat ÜZER for his valuable support in improving this paper.

References

  1. References
  2. 1. Schmidt, M., Sørensen. H,T., and Pedersen, L., Cardiovascular Risks of Diclofenac Versus Other Older COX-2 Inhibitors (Meloxicam and Etodolac) and Newer COX-2 Inhibitors (Celecoxib and Etoricoxib): A Series of Nationwide Emulated Trials. Drug Safety, 2022. 45.9: p. 983–994. https://doi.org/10.1007/s40264-022-01211-1
  3. 2. Porat, D., Dukhno, O., Partook-Maccabi, M., Vainer, E., Cvijić, S., and Dahan, A., Selective COX-2 inhibitors after bariatric surgery: Celecoxib, etoricoxib and etodolac post-bariatric solubility/dissolution and pharmacokinetics. International Journal of Pharmaceutics, 2023. 645. p. 123347-123362. https://doi.org/10.1016/j.ijpharm.2023.123347
  4. 3. Alanazi, A.Z., Alhazzani, K., Mostafa, A.M., Barker. J., El-Wekil. M.M., Ali. A.M.B.H., Selective and reliable fluorometric quantitation of anti-cancer drug in real plasma samples using nitrogen-doped carbon dots after MMIPs solid phase microextraction: Monitoring methotrexate plasma level. Journal of Pharmaceutical and Biomedical Analysis, 2024. 238 115862-115869. https://doi.org/10.1016/j.jpba.2023.115862
  5. 4. Dogruer-Erkok, S., Gallois, R., Leegwater, L., Gonzalez, P.C, van Asten A, and McCord B., Combining surface-enhanced Raman spectroscopy (SERS) and paper spray mass spectrometry (PS-MS) for illicit drug detection. Talanta, 2024. 278. p.126414-126425. https://doi.org/10.1016/j.talanta.2024.126414
  6. 5. Picollo, M., Aceto, M., and Vitorino, T., UV-Vis spectroscopy. Physical Sciences Reviews, 2019. 4.4. https://doi.org/10.1515/psr-2018-0008
  7. 6. Li, F., Wang, X., Yang, M., Zhu, M., Chen, W., Li, Q., Sun, D., Bi, X., Maletskyi, Z., and Ratnaweera, H., Detection Limits of Antibiotics in Wastewater by Real-Time UV–VIS Spectrometry at Different Optical Path Length. Processes, 2022. 10.12: p.2614-2628. https://doi.org/10.3390/pr10122614
  8. 7. Kumar, A.K.H., Sudha, V., Swaminathan, S., and Ramachandran, G., Comparison of HPLC & spectrophotometric methods for estimation of antiretroviral drug content in pharmaceutical products. The Indian Journal of Medical Research, 2010. 132.10: p.390-394.

Details

Primary Language

English

Subjects

Pharmacology and Pharmaceutical Sciences (Other)

Journal Section

Research Article

Early Pub Date

December 15, 2025

Publication Date

December 23, 2025

Submission Date

June 12, 2025

Acceptance Date

August 14, 2025

Published in Issue

Year 2025 Volume: 8 Number: 3

APA
Adib, H., Karimpour, I., & Akay Sazaklioglu, S. (2025). Development of a UV-Vis Spectroscopic Method for Etodolac Determination and Evaluation of Pharmaceutical Additive Effects. International Journal of Life Sciences and Biotechnology, 8(3), 178-186. https://doi.org/10.38001/ijlsb.1717622
AMA
1.Adib H, Karimpour I, Akay Sazaklioglu S. Development of a UV-Vis Spectroscopic Method for Etodolac Determination and Evaluation of Pharmaceutical Additive Effects. Int. J. Life Sci. Biotechnol. 2025;8(3):178-186. doi:10.38001/ijlsb.1717622
Chicago
Adib, Hosna, Iraj Karimpour, and Sevda Akay Sazaklioglu. 2025. “Development of a UV-Vis Spectroscopic Method for Etodolac Determination and Evaluation of Pharmaceutical Additive Effects”. International Journal of Life Sciences and Biotechnology 8 (3): 178-86. https://doi.org/10.38001/ijlsb.1717622.
EndNote
Adib H, Karimpour I, Akay Sazaklioglu S (December 1, 2025) Development of a UV-Vis Spectroscopic Method for Etodolac Determination and Evaluation of Pharmaceutical Additive Effects. International Journal of Life Sciences and Biotechnology 8 3 178–186.
IEEE
[1]H. Adib, I. Karimpour, and S. Akay Sazaklioglu, “Development of a UV-Vis Spectroscopic Method for Etodolac Determination and Evaluation of Pharmaceutical Additive Effects”, Int. J. Life Sci. Biotechnol., vol. 8, no. 3, pp. 178–186, Dec. 2025, doi: 10.38001/ijlsb.1717622.
ISNAD
Adib, Hosna - Karimpour, Iraj - Akay Sazaklioglu, Sevda. “Development of a UV-Vis Spectroscopic Method for Etodolac Determination and Evaluation of Pharmaceutical Additive Effects”. International Journal of Life Sciences and Biotechnology 8/3 (December 1, 2025): 178-186. https://doi.org/10.38001/ijlsb.1717622.
JAMA
1.Adib H, Karimpour I, Akay Sazaklioglu S. Development of a UV-Vis Spectroscopic Method for Etodolac Determination and Evaluation of Pharmaceutical Additive Effects. Int. J. Life Sci. Biotechnol. 2025;8:178–186.
MLA
Adib, Hosna, et al. “Development of a UV-Vis Spectroscopic Method for Etodolac Determination and Evaluation of Pharmaceutical Additive Effects”. International Journal of Life Sciences and Biotechnology, vol. 8, no. 3, Dec. 2025, pp. 178-86, doi:10.38001/ijlsb.1717622.
Vancouver
1.Hosna Adib, Iraj Karimpour, Sevda Akay Sazaklioglu. Development of a UV-Vis Spectroscopic Method for Etodolac Determination and Evaluation of Pharmaceutical Additive Effects. Int. J. Life Sci. Biotechnol. 2025 Dec. 1;8(3):178-86. doi:10.38001/ijlsb.1717622



Follow us on social networks  19277 19276 20153  22366